Suppr超能文献

E46K 突变型 α-突触核蛋白可被蛋白酶体和巨自噬途径降解。

E46K Mutant α-Synuclein Is Degraded by Both Proteasome and Macroautophagy Pathway.

机构信息

Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica and Neuroscience Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

出版信息

Molecules. 2018 Nov 1;23(11):2839. doi: 10.3390/molecules23112839.

Abstract

Genetic studies have revealed that rare mutations and multiplications of the gene locus in α-synuclein (α-syn) are implicated in the pathogenesis of Parkinson's disease (PD). However, the pathological effects of α-syn are still obscure. The neurotoxicity of α-syn is mainly determined by its protein levels, which depend on a balance between synthesis and degradation. Therefore, verifying the possible routes contributing to the clearance of α-syn is important for PD therapy. In this study, we established stable lines overexpressing human wild-type (WT) and E46K mutant α-syn in rat PC12 cells and investigated the degradation pathways of α-syn by using a panel of inhibitors and inducers of lysosome and proteasome function. We also monitored the degradation kinetics of α-syn by using cycloheximide to block protein synthesis. Our data showed that both proteasome and chaperon-mediated autophagy (CMA) are responsible for the degradation of the WT α-syn. Meanwhile, E46K mutant α-syn is mainly degraded by the proteasome and macroautophagy pathway. Compared with the WT protein, E46K mutant α-syn turned over more slowly in PC12 cells. In addition, overexpression of E46K mutant α-syn increased vulnerability of PC12 cells to apoptosis insults when compared with WT α-syn. Our findings may verify the possible routes contributing to the degradation of the E46K mutant α-syn.

摘要

遗传研究表明,α-突触核蛋白(α-syn)基因座的罕见突变和倍增与帕金森病(PD)的发病机制有关。然而,α-syn 的病理作用仍不清楚。α-syn 的神经毒性主要由其蛋白水平决定,这取决于合成和降解之间的平衡。因此,验证可能有助于清除α-syn 的途径对于 PD 治疗很重要。在这项研究中,我们在大鼠 PC12 细胞中建立了稳定表达人野生型(WT)和 E46K 突变体α-syn 的细胞系,并使用一系列溶酶体和蛋白酶体功能的抑制剂和诱导剂来研究α-syn 的降解途径。我们还通过使用环己酰亚胺阻断蛋白合成来监测α-syn 的降解动力学。我们的数据表明,蛋白酶体和伴侣介导的自噬(CMA)都负责 WT α-syn 的降解。同时,E46K 突变体α-syn 主要通过蛋白酶体和巨自噬途径降解。与 WT 蛋白相比,E46K 突变体α-syn 在 PC12 细胞中的周转率更慢。此外,与 WT α-syn 相比,E46K 突变体α-syn 的过表达增加了 PC12 细胞对凋亡损伤的易感性。我们的发现可能验证了可能有助于降解 E46K 突变体α-syn 的途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a31/6278282/6e5f2b69374c/molecules-23-02839-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验